U.S. venture capitalists are decreasing investments in biopharmaceutical and medical device companies, reducing their concentration in prevalent disease areas, and shifting investment away from the United States toward Europe and Asia. The report released by the National Venture Capital Association shows that more than 150 venture capital firms identified regulatory challenges from the Food and […]
This content is only available to members of the CSBJ. To gain access, you'll need to sign in or purchase Digital, Silver Membership, Print & Digital, Print, Digital and The Transcript, Corporate Membership or Digital Monthly If you're already a member, sign in here.